|Bid||80.00 x 1300|
|Ask||83.31 x 800|
|Day's Range||81.23 - 83.99|
|52 Week Range||62.48 - 110.37|
|Beta (5Y Monthly)||1.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 11, 2021 - Feb 15, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||102.13|
The global Ethernet testing market is expected to reach $2 billion by 2025, with North America leading the waySANTA CLARA, Calif., Nov.
The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer
Lilly's (LLY) rheumatoid arthritis drug, Olumiant gets Emergency Use Authorization for treating hospitalized COVID-19 patients in combination with Gilead's Veklury.